Artemether Combined with shRNA Interference of Vascular Cell Adhesion Molecule-1 Significantly Inhibited the Malignant Biological Behavior of Human Glioma Cells

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Wang, Ying Bin ^a   Hu, Yi ^a   Li, Zhen ^a   Wang, Ping ^a   Xue, Yi Xue ^a   Yao, Yi Long ^a   Yu, Bo ^a   Liu, Yun Hui ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ARTEMETHER; FLUORESCEIN ISOTHIOCYANATE; GELATINASE A; GELATINASE B; LIPOCORTIN 5; PROTEIN KINASE B; SHORT HAIRPIN RNA; VASCULAR CELL ADHESION MOLECULE 1;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL INVASION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GENE SILENCING; GLIOMA; GLIOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MIGRATION INHIBITION; PROTEIN EXPRESSION; RNA INTERFERENCE; WESTERN BLOTTING;

ANNEXIN A5; APOPTOSIS; ARTEMISININS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL MOVEMENT; DRUGS, CHINESE HERBAL; FLUORESCEIN-5-ISOTHIOCYANATE; GLIOMA; HUMANS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM INVASIVENESS; RNA INTERFERENCE; RNA, SMALL INTERFERING; TETRAZOLIUM SALTS; THIAZOLES; VASCULAR CELL ADHESION MOLECULE-1;

EID: 84876120652     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060834     Document Type: Article

References (55)

1. Sanai N, Berger MS, (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62: 753-766.
2. Siebzehnrubl FA, Reynolds BA, Vescovi A, Steindler DA, Deleyrolle LP, (2011) The origins of glioma: E Pluribus Unum? Glia 59: 1135-1147.
3. Stupp R, Mason WP, Van den Bent MJ, Weller M, Fisher B, et al. (2005) Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med 352: 987-996.
4. Lima FRS, Kahn SA, Soletti RC, Biasoli D, Alves T, et al. (2012) Glioblastoma: Therapeutic challenges, what lies ahead. Biochimica et biophysica acta 1826: 338-349.
5. Florio T, Barbieri F, (2012) The status of the art of human malignant glioma management: the promising role of targeting tumor-initiating cells. Drug discovery today 17: 1103-1110.
6. Hai J, Lin Q, Lu Y, Yi J, Zhang H, (2008) Growth inhibition and induction of differentiation by panaxydol in rat C6 glioma cells. Neurological research 30: 99-105.
7. Shao J, Zheng D, Jiang Z, (2011) Curcumin delivery by methoxy polyethylene glycol-poly (caprolactone) nanoparticles inhibits the growth of C6 glioma cells. Acta Biochim Biophys Sin 43: 267-274.
8. Nakase I, Lai H, Singh NP, Sasaki T, (2008) Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. International journal of pharmaceutics 354: 28-33.
9. Chen H, (2003) Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacological Research 48: 231-236.
10. Zhang CZ, Zhang H, Yun J, Chen GG, Lai PBS, (2012) Dihydroartemisinin exhibits antitumor activity toward hepatocellular carcinoma in vitro and in vivo. Biochemical pharmacology 83: 1278-1289.
11. Li Y, Wu YL, (1998) How Chinese scientists discovered qinghaosu (artemisinin) and developed its derivatives? What are the future perspectives? Med Trop 58: 9-12.
12. Kamugisha E, Jing S, Minde M, Kataraihya J, Kongola G, et al. (2012) Efficacy of artemether-lumefantrine in treatment of malaria among under-fives and prevalence of drug resistance markers in Igombe-Mwanza, north-western Tanzania. Malaria Journal 11: 58. Malaria Journal website. Available: http://www.malariajournal.com/content/11/1/58. Accessed 2012 November 13.
13. Farsam V, Hassan ZM, Zavaran-Hosseini A, Noori S, Mahdavi M, et al. (2011) Antitumor and immunomodulatory properties of artemether and its ability to reduce CD4+ CD25+ FoxP3+ T reg cells in vivo. International immunopharmacology 11: 1802-1808.
14. Alcântara DDFÁ, Ribeiro HF, Cardoso PCDS, Araújo TMT, Burbano RR, et al. (2013) In vitro evaluation of the cytotoxic and genotoxic effects of artemether, an antimalarial drug, in a gastric cancer cell line (PG100). Journal of applied toxicology 33: 151-156.
15. Wu Z-P, Gao C-W, Wu Y-G, Zhu Q-S, Yan Chen, et al. (2009) Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. Integrative cancer therapies 8: 88-92.
16. Efferth T, Olbrich A, Bauer R, (2002) mRNA expression profiles for the response of human tumor cell lines to the antimalarial drugs artesunate, arteether, and artemether. Biochemical pharmacology 64: 617-623.
17. Manning L, Laman M, Page-Sharp M, Salman S, Hwaiwhanje I, et al. (2011) Meningeal inflammation increases artemether concentrations in cerebrospinal fluid in Papua New Guinean children treated with intramuscular artemether. Antimicrobial agents and chemotherapy 55: 5027-5033.
18. Gautam A, Ahmed T, Batra V, Paliwal J, (2009) Pharmacokinetics and pharmacodynamics of endoperoxide antimalarials. Current drug metabolism 10: 289-306.
19. Xie LH, Li Q, Zhang J, Weina PJ (2009) Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats. Malaria journal 8: 112. Malaria Journal website. Available: http://www.malariajournal.com/content/8/1/112. Accessed 2012 November 13.
20. Wang D, Anderson JC, Gladson CL, (2005) The role of the extracellular matrix in angiogenesis in malignant glioma tumors. Brain pathology 15: 318-326.
21. Mäenpää a, Kovanen PE, Paetau A, Jäáskeläinen J, Timonen T, (1997) Lymphocyte adhesion molecule ligands and extracellular matrix proteins in gliomas and normal brain: expression of VCAM-1 in gliomas. Acta neuropathologica 94: 216-225.
22. Zhan Q, Yue W, Shaoshan H, (2011) The inhibitory effect of photodynamic therapy and of an anti-VCAM-1 monoclonal antibody on the in vivo growth of C6 glioma xenografts. Brazilian Journal of Medical and Biological Research 44: 489-490.
23. Forsyth PA, Wong H, Laing TD, Rewcastle NB, Morris DG, et al. (1999) Gelatinase-A (MMP-2), gelatinase-B (MMP-9) and membrane type matrix metalloproteinase-1 (MT1-MMP) are involved in different aspects of the pathophysiology of malignant gliomas. British Journal of Cancer 79: 1828-1835.
24. Zhao JX, Yang LP, Wang YF, Qin LP, Liu DQ, et al. (2007) Gelatinolytic activity of matrix metalloproteinase-2 and matrix metalloproteinase-9 in rat brain after implantation of 9L rat glioma cells. European journal of neurology 14: 510-516.
25. Wang M, Yoshida D, Liu S, Teramoto A, (2005) Inhibition of cell invasion by indomethacin on glioma cell lines: in vitro study. Journal of neuro-oncology 72: 1-9.
26. Okkenhaug K, Vanhaesebroeck B, (2003) PI3K in lymphocyte development, differentiation and activation. Nature reviews Immunology 3: 317-330.
27. Kubiatowski T, Jang T, Lachyankar MB, Salmonsen R, Nabi RR, et al. (2001) Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas. J Neurosurg 95: 480-488.
28. Hu Y, Cheng P, Xue YX, Liu YH, (2012) Glioma cells promote the expression of vascular cell adhesion molecule-1 on bone marrow-derived mesenchymal stem Cells: a possible mechanism for their tropism toward gliomas. J Mol Neurosci 48: 127-35.
29. Geisberger G, Gyenge EB, Maake C, Patzke GR, (2013) Trimethyl and carboxymethyl chitosan carriers for bio-active polymer-inorganic nanocomposites. Carbohydrate polymers 91: 58-67.
30. Shiozaki A, Bai X, Shen-Tu G, Moodley S, Takeshita H, et al. (2012) Claudin 1 mediates TNFα-induced gene expression and cell migration in human lung carcinoma cells. PloS one 7: e38049 Doi: 10.1371/journal.pone.0038049.
31. Roos N, Poulalhon N, Farge D, Madelaine I, Mauviel A, (2007) In vitro evidence for a direct antifibrotic role of the immunosuppressive drug Mycophenolate Mofetil. J Pharmacol Exp Ther 321: 583-589.
32. Qi S, Song Y, Peng Y, Wang H, Long H, et al. (2012) ZEB2 mediates multiple pathways regulating cell proliferation, migration, invasion, and apoptosis in glioma. PloS one 7: e38842 Doi: 10.1371/journal.pone.0038842.
33. Bai J, Mei P-J, Liu H, Li C, Li W, et al. (2012) BRG1 expression is increased in human glioma and controls glioma cell proliferation, migration and invasion in vitro. Journal of cancer research and clinical oncology 138: 991-998.
34. Sariahmetoglu M, Crawford B, Leon H, Sawicka O, Li L, et al. (2007) Regulation of matrix metalloproteinase-2 (MMP-2) activity by phosphorylation. The FASEB Journal 21: 2486-2495.
35. Lai S-L, Cheah S-C, Wong P-F, Noor SM, Mustafa MR, (2012) In vitro and in vivo anti-angiogenic activities of Panduratin A. PloS one. 7: e38103 Doi: 10.1371/journal.pone.0038103.
36. Shabaik YH, Millard M, Neamati N, (2013) Mechanistic evaluation of a novel small molecule targeting mitochondria in pancreatic cancer cells. PloS one 8: e54346 Doi: 10.1371/journal.pone.0054346.
37. Lodge NJ, Lelas S, Li Y-W, Molski T, Grace J, et al. (2013) Pharmacological and behavioral characterization of the novel CRF(1) antagonist BMS-763534. Neuropharmacology 67: 284-293.
38. Kokwaro GO, (1998) Use of Artemisinin (Qinghaosu) derivatives in the treatment of malaria. African journal of health sciences 5: 8-11.
39. Okell LC, Drakeley CJ, Bousema T, Whitty CJM, Ghani AC, (2008) Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity. PLoS medicine 5: e226 Doi: 10.1371/journal.pmed.0050226.
40. Hou J, Wang D, Zhang R, Wang H, (2008) Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and mechanisms of action. Clinical cancer research 14: 5519-5530.
41. Singh NP, Panwar VK, (2006) Case report of a pituitary macroadenoma treated with artemether. Integrative cancer therapies 5: 391-394.
42. Fishwick J, Mclean WG, Edwardsatb G, Ward SA, (1995) The toxicity of artemisinin and related compounds on neuronal and glial cells in culture. Chemico-biological interactions 96: 263-271.
43. Koch AE, Halloran MM, Haskell CJ, Shah MR, Polverini PJ, (1995) Angiogenesis mediated by soluble forms of E-selectin and vascular cell adhesion molecule-1. Nature 376: 517-519.
44. Ding Y-B, Chen G-Y, Xia J-G, Zang X-W, Yang H-Y, et al. (2003) Association of VCAM-1 overexpression with oncogenesis, tumor angiogenesis and metastasis of gastric carcinoma. World journal of gastroenterology 9: 1409-1414.
45. Maurer CA, Friess H, Kretschmann B, Wildi S, Müller C, et al. (1998) Over-expression of ICAM-1, VCAM-1 and ELAM-1 might influence tumor progression in colorectal cancer. International journal of cancer 79: 76-81.
46. Klemke M, Weschenfelder T, Konstandin MH, Samstag Y, (2007) High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers. Journal of cellular physiology 212: 368-374.
47. Horn L, Dahlberg SE, Sandler AB, Dowlati A, Moore DF, et al. (2009) Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. Journal of clinical oncology 27: 6006-6011.
48. Deem TL, Cook-Mills JM, (2004) Vascular cell adhesion molecule 1 (VCAM-1) activation of endothelial cell matrix metalloproteinases: role of reactive oxygen species. Blood 104: 2385-2393.
49. Levine D, Bogomolniy F, Yee CJ, Lash A, Barakat RR, et al. (2005) Frequent mutation of the PIK3CA gene in ovarian and breast cancers. Clinical cancer research 11: 2875-2878.
50. Uegaki K, Kanamori Y, Kigawa J, Kawaguchi W, Kaneko R, et al. (2005) PTEN-positive and phosphorylated-Akt-negative expression is a predictor of survival for patients with advanced endometrial carcinoma. Oncology reports 14: 389-392.
51. Hartmann W, Digon-Söntgerath B, Koch A, Waha A, Endl E, et al. (2006) Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clinical cancer research 12: 3019-3027.
52. Nyåkern M, Tazzari PL, Finelli C, Bosi C, Follo MY, et al. (2006) Frequent elevation of Akt kinase phosphorylation in blood marrow and peripheral blood mononuclear cells from high-risk myelodysplastic syndrome patients. Leukemia 20: 230-238.
53. Pu P, Kang C, Zhang Z, Al E, (2006) Downregulation of PIK3CB by siRNA suppresses malignant glioma cell growth in vitro and in vivo. Technol Cancer Res Treat 5: 271-280.
54. Pu P, Kang C, Li J, Jiang H, Cheng J, (2006) The effects of antisense AKT2 RNA on the inhibition of malignant glioma cell growth in vitro and in vivo. Journal of neuro-oncology 76: 1-11.
55. Pu P, Kang C, Li J, Jiang H, (2004) Antisense and dominant-negative AKT2 cDNA inhibits glioma cell invasion. Tumour biology 25: 172-178.